Lu AF35700 + Risperidone + Olanzapine
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment-resistant Schizophrenia
Conditions
Treatment-resistant Schizophrenia
Trial Timeline
Jul 20, 2017 → Feb 5, 2019
NCT ID
NCT03230864About Lu AF35700 + Risperidone + Olanzapine
Lu AF35700 + Risperidone + Olanzapine is a phase 3 stage product being developed by Lundbeck for Treatment-resistant Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03230864. Target conditions include Treatment-resistant Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03230864 | Phase 3 | Terminated |
Competing Products
6 competing products in Treatment-resistant Schizophrenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection | Novartis | Phase 2 | 52 |
| MIJ821 + Placebo + Ketamine | Novartis | Phase 2 | 52 |
| Mifepristone 1200 mg daily + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| GH001 + Placebo | GH Research | Phase 2 | 47 |
| VLY-686 + Placebo | Vanda Pharmaceuticals | Phase 2 | 44 |
| Evenamide 15 mg bid + Placebo | Newron Pharmaceuticals | Phase 3 | 69 |